PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Stephanie Hachtel	02/27/2009
Juergen Dedio	03/13/2009
Josef Pernerstorfer	02/27/2009
Stephen Shimshock	03/12/2009
Carolina Lanter	03/08/2009

RECEIVING PARTY DATA

Name:	sanofi-aventis	
Street Address:	174 Avenue de France	
City:	Paris	
State/Country:	FRANCE	
Postal Code:	75013	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12337980

CORRESPONDENCE DATA

Fax Number: (908)231-2626

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 908-231-5705

Email: linda.remer@sanofi-aventis.com

Correspondent Name: Brian R. Morrill

Address Line 1: 1041 Route 202-206

Address Line 2: Mail Code: D303-A

Address Line 4: Bridgewater, NEW JERSEY 08807

ATTORNEY DOCKET NUMBER: DE2006/024 US CNT

NAME OF SUBMITTER: Linda J. Remer

PATENT

REEL: 022953 FRAME: 0121

:H \$40.00 12;

500909781

Total Attachments: 3

source=DE2006024USCNTASGN#page1.tif source=DE2006024USCNTASGN#page2.tif source=DE2006024USCNTASGN#page3.tif

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Stephanie Hachtel, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 2) Dr. Juergen Dedio, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Josef Pernerstorfer, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Stephen Shimshock, sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, NJ 08807, USA
- 5) Carolina Lanter, sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, NJ 08807, USA

The inventors are citizens of: 1) - 3) Germany; 4) and 5) USA

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: **12/337980**

filed: December 18, 2008

entitled: CXCR2 inhibitors

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

HIVE	mtor(s):	
1 st :	Sapranic Huchtel	Date: 27 Cr. 2003
2 nd :	Jurga John	Date: 12.3.2009
	ful II	Date: 27/2/2009
4 th :		Date:
5 th :		Date:

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged.

!/we

- Dr. Stephanie Hachtel, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- Dr. Juergen Dedio, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Josef Pernerstorfer, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Stephen Shimshock, sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, NJ 08807, USA
- 5) Carolina Lanter, sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, NJ 08807, USA

The inventors are citizens of: 1) - 3) Germany; 4) and 5) USA

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France. located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/337980

filed:

December 18, 2008

entitled:

CXCR2 inhibitors

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

inventor(s):			
get.		Date:	
2 ⁷⁷⁴ :		Date:	
310:		Date:	
4 th .	Light Shirth	Date: //www.// /2., 2005	
5 th :	<u></u>	Date:	

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

l/we

- 1) Dr. Stephanie Hachtel, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 2) Dr. Juergen Dedio, c/o Sanoti-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Josef Pernerstorfer, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Stephen Shimshock, sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, NJ 08807, USA
- 5) Carolina Lanter, sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, NJ 08807, USA

The inventors are citizens of 1) - 3) Germany; 4) and 5) USA

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/337980

RECORDED: 07/14/2009

filed: December 18, 2008

entitled: CXCR2 inhibitors

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

inven	itor(s):		
1 st ,		•••••	Date:
2 nd .			Date:
3 rd : _			Date:
4 ³¹ :			Date:
5 ⁱⁿ .	Laudenie	L. Landon	Date: 77/2022 8 2009